FDA Submission Status Update for ANDA220197 by Aizant Drug Research Solutions
The FDA has received ANDA220197 from Aizant Drug Research Solutions, currently under standard review.
Asset / Drug
Drug and asset intelligence for ANDA220197 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.